[Pubmed] IL-6 receptor antibody treatment improves muscle weakness in experimental autoimmune myasthenia gravis mouse mo
Posté : 16 mai 2024 12:00
Front Neurol. 2024 May 1;15:1356300. doi: 10.3389/fneur.2024.1356300. eCollection 2024.
ABSTRACT
Myasthenia gravis (MG) is a chronic autoimmune disease characterized by muscle weakness and fatigue. It is caused by pathological autoantibodies against components expressed at neuromuscular junctions, such as acetylcholine receptor (AChR). Interleukin-6 (IL-6) has been suggested to play a role in the pathogenesis of MG, and IL-6 receptor (IL-6R) antibody treatment may provide a novel therapeutic option. In this study, we investigated the effects of IL-6R antibody treatment in an experimental autoimmune MG (EAMG) mouse model. We demonstrated that IL-6R antibody treatment improved muscle weakness, reduced IgG deposition at neuromuscular junctions, and the levels of AChR autoantibodies in serum. In addition, follicular helper T cells and Th17, plasma cells in lymph nodes were lower in IL-6R antibody treated mice. Our findings suggest that IL-6R blockade may be a novel and effective therapeutic strategy for the treatment of MG.
PMID:38751878 | PMC:PMC11094227 | DOI:10.3389/fneur.2024.1356300
Source: https://pubmed.ncbi.nlm.nih.gov/3875187 ... t9+e462414